期刊文献+

调脂胶囊对实验性动脉粥样硬化大鼠主动脉ICAM-1表达的影响 被引量:4

Influence of Tiaozhi capsule on expression of ICAM-1 in rats
下载PDF
导出
摘要 目的探讨调脂胶囊抗动脉粥样硬化的作用及其机制。方法用维生素D3和高脂饲料诱发大鼠动脉粥样硬化。雄性SD大鼠随机分为正常组,模型组,调脂胶囊高,中,低剂量组及辛伐他汀组。给药10周后,酶比色法检测各组大鼠血清和组织超氧化物歧化酶(SOD)活性和丙二醛(MDA)的含量。RT-PCR方法检测主动脉壁ICAM-1 mRNA表达水平。结果治疗组MDA含量均明显降低,SOD活性增高。调脂胶囊能减少ICAM-1基因的表达,且高剂量组作用更为明显。结论调脂胶囊具有抗动脉粥样硬化作用,其抗氧化和下调主动脉ICAM-1表达可能是其作用机制之一。 Objective To investigate the mechanism of anti-atherosclerosis of Tiaozhi capsule. Methods 60 male SD rats were randomly divided into 6 groups, including control group, model group, simvastatin group, high dose Tiaozhi group, middle dose Tiaozhi group and low dose Tiaozhi group. The model of atherosclerosis was established with feeding high cholesterol diet and vitamin D3. After 10 weeks, the super oxide dismutase (SOD) and maleic dialdehyde (MDA) were detected with enzyme colorimetric method. ICAM-1-mRNA in aortic wall was detected with RT-PCR. Resuits SOD of groups treated with Tiaozhi obviously increased compare with those of model group, whereas MDA decreased. The levels of ICAM-1 mRNA in each treated group were significantly lower than that in model group. The high dose Tiaozhi group demonstrated much better results than the other groups. Conclusion Tiaozhi capsule shows effects of anti-atherosclerosis, whose mechanism maybe involve in down-regulating the expression of ICAM-1 in artery vessels.
出处 《西部医学》 2009年第2期185-187,共3页 Medical Journal of West China
关键词 调脂胶囊 动脉粥样硬化 细胞间粘附分子 氧自由基 Tiaozhi capsule Atherosclerosis Intercellular adhesion molecule Oxyradical
  • 相关文献

参考文献5

二级参考文献19

  • 1王巍,陈可冀.中国传统调脂药物研究的现状和前景[J].中国中西医结合杂志,1994,14(10):635-637. 被引量:57
  • 2中华人民共和国卫生部药政局.中药新药临床研究指导原则(第一、二批合订本)[M].北京:中华人民共和国卫生部制定发布,1989.171-174.
  • 3徐叔云.降血脂药及抗动脉硬化药的筛选法.药理实验方法学[M].北京:人民卫生出版社,1985.781-783.
  • 4Steinberg D, Parthasarathy S, Carew T E, et al. Beyond cholesterol, modifications of LDL that increase its atherogenicity. N Engl J Med, 1989,302:915.
  • 5Michael A W. Lipid peroxidation in relation to prostacyclin and thromboxane: physiology and pathophysiology. Br Med Bull,1983,39:277.
  • 6Pakala R,Dilcher C,Baffour R,et al.Peroxisome Proliferator-Activated Receptor[gamma]Ligand Pioglitazone AltersNeointimal Composition in a Balloon-Denuded and RadiatedHypercholesterolemic Rabbit[].Journal of Cardiovascular Pharmacology.2006
  • 7Marx N,Bourcier T,Sukhova GK,et al.PPARgammaactivation in human endothelial cells increases plasminogenactivator inhibitor type-1 expression:PPARgamma as apotential mediator in vascular disease[].Arteriosclerosis Thrombosis and Vascular Biology.1999
  • 8Martens F,Rabelink T,Roodt J,et al.TNF-[alpha]inducesendothelial dysfunction in diabetic adults,an effect reversible bythe PPAR-[gamma]agonist pioglitazone[].European Heart Journal.2006
  • 9Solt B,Akos K,Gabor K.PPARγactivation,by reducingoxidative stress,increases NO bioavailability in coronaryarterioles of mice with Type 2 diabetes[].American Journal of Physiology Heart and Circulatory Physiology.2004
  • 10Noue I,Goto S,Matsunaga T,et al.The ligands/activators forperoxisome proliferato proliferator-activated receptor(PPAR)and PPARγincrease Cu2+,Zn2+-superoxide dismutase anddecrease p22phox message expressions in primary endothelialcells[].Metabolism.2001

共引文献78

同被引文献84

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部